SpinaFX Receives the US FDA IDE Approval to Initiate Trial for Triojection Therapy

Why It Matters

The study could validate a less invasive alternative to surgery, potentially reshaping lumbar disc treatment and opening new reimbursement opportunities for spine specialists.

Key Takeaways

• FDA grants IDE for Triojection therapy targeting lumbar disc herniation
• Trial will enroll 300 patients at ~30 specialty spine centers
• Combines intradiscal ozone/oxygen injection with nerve root block
• Primary endpoints include pain relief and functional improvement up to 24 months
• Study will collect safety and health‑economics data for reimbursement

Pulse Analysis

Lumbar disc herniation remains a leading cause of chronic back pain, affecting millions of Americans and driving substantial healthcare expenditures. While many patients respond to physical therapy, anti‑inflammatories, or epidural steroid injections, a sizable subset fails to achieve relief, often progressing to costly surgical interventions such as discectomy or fusion. The clinical community has long sought minimally invasive options that can address disc pathology directly while preserving spinal stability and reducing recovery time.

SpinaFX’s Triojection therapy enters this space with an FDA‑approved IDE, allowing the company to test a novel combination of intradiscal ozone/oxygen injection and a nerve‑root block. The multicenter, randomized trial will compare this dual approach against the standard nerve‑root block in roughly 300 patients across 30 spine centers. By measuring pain scores, functional indices, and quality‑of‑life outcomes at multiple intervals up to two years, the study aims to produce robust efficacy and safety data. Importantly, the protocol also captures health‑economics metrics, positioning the therapy for potential reimbursement discussions if outcomes prove favorable.

If successful, Triojection could disrupt the current treatment algorithm for contained lumbar disc herniations, offering clinicians a less invasive, office‑based alternative that shortens recovery and lowers overall costs. Payers may view the therapy favorably given its potential to reduce surgical rates and associated complications. Moreover, the trial’s health‑economics component could provide the evidence base needed for coding and coverage decisions, accelerating market adoption and establishing SpinaFX as a key player in the evolving spine‑care landscape.